NewsRoom Articles - Page 62 of 154 - PsychedelicNewsWire (PNW)

MondayApr 18, 2022 12:31 pm

Machine Learning Model Enables Researchers to Pinpoint PTSD Sufferers

Researchers have designed a machine learning model that can identify individuals suffering from PTSD by conducting an analysis of text data with 80% accuracy. Post-traumatic stress disorder (PTSD) is a mental health condition that is triggered by a traumatic event which an individual may witness or experience. This machine learning model may, in the future, be used as an inexpensive and accessible screening method to help physicians detect and diagnose post-traumatic stress disorder or other mental conditions, via telehealth platforms. Jeff Sawalha, a PhD candidate specializing in psychiatry at the University of Alberta, led this project. He carried out an…

MondayApr 18, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

World Intellectual Property Organization has published CYBN’s international patent application Publication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment options Company continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled "Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods," further strengthens Cybin’s long-term intellectual property (“IP”) position related to psychedelic-based programs. The application covers an array of inhalation delivery…

MondayApr 18, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Continues Expansion to Make Science-Backed Psychedelic Medicines Accessible to Patients with Mental Health Conditions

Delic opened two new KWC clinics in Q1 2022, bringing the total number of locations to 13, with plans to open more within the next 18 months The company also saw the introduction of SPRAVATO(R) nasal spray as a treatment option for treatment-resistant depression It is also expanding its ability to research novel compounds and develop IP for future commercialization Delic Holdings' (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Chief Executive Officer (“CEO”) and Co-founder, Matt Stang, has been keen to note the company’s commitment to bringing psychedelic medicine closer to individuals dealing with mental health conditions, particularly those with treatment-resistant…

ThursdayApr 14, 2022 4:00 pm

Psychedelics Could Help Combat Alcoholism

Recently conducted studies have found that psychedelics may be useful in the treatment of various mental conditions, including anxiety, depression and alcoholism. “Psychedelic” is a term coined by Dr. Humphry Osmond in the 20th century. Osmond, who specialized in psychiatry, theorized that some mental illnesses were brought about by chemical imbalances in the brain. Through his research in the ‘50s, he discovered that these hallucinogenic substances could be used to treat alcoholism. Alcoholism, or alcohol-use disorder, is defined as an addiction to drinking alcohol. The disorder develops as an individual drinks so much alcohol that their body becomes dependent on…

WednesdayApr 13, 2022 2:52 pm

New Study Highlights How Sleep Patterns Are Impacted by Psilocybin

A new study has found that psilocybin causes temporary changes to the basic structural organization of normal sleep in lab mice. Professor Vladyslav V. Vyazovskiy of the University of Oxford, who conducted the study, stated that evidence had shown that psychedelics such as psilocybin could rapidly reduce core symptoms of various psychiatric conditions, even in serious cases that were resistant to other treatments. The researchers’ objective was to examine the potential impact that psilocybin had on sleep, as sleep disturbance contributed to the continuation as well as the onset of diverse mental illnesses. For their study, the researchers used animal…

WednesdayApr 13, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Introduces FDA-Approved SPRAVATO(R) Nasal Spray at KWC Clinics in a Move to Make Mental health Treatment Effective and Affordable

Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1 SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, has remained committed to expanding its ability to research novel compounds and developing intellectual property (“IP”) for future commercialization of novel psychedelic compounds for medical use. So far,…

TuesdayApr 12, 2022 2:17 pm

Legislators in Colorado Pass MDMA Initiative But Reject Broader Psychedelics Proposal

Earlier last week, legislators in Colorado passed a measure that aligns statutes in the state to legalize MDMA prescriptions if the federal government allows its use. MDMA, which is commonly referred to as ecstasy, has shown promise in its use as a treatment for various indications, including anxiety and PTSD. The legislators made their decision after hearing testimonies from a number of people, including a military veteran who admitted that MDMA had helped him manage his post-traumatic stress disorder. This measure, which was unanimously approved, is being advanced to the floor. The House Public & Behavioral Health & Human Services…

TuesdayApr 12, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio For 2022, the company plans to build on the progress achieved in 2021 With new additions to its board, its conditional IRB approval, and the clinical research it has lined up for the new year, Mydecine is confident that it will meet its anticipated capital markets initiatives for 2022 Founded in 2020, Mydecine Innovations Group (NEO: MYCO)…

MondayApr 11, 2022 2:50 pm

Top Federal Official Highlights Need to Enact Policy Changes for More Psychedelic Research to Be Conducted

During an event last week, top drug officials explained how the classification of substances such as cannabis and some psychedelics under Schedule I of the Controlled Substances Act hindered studies into the therapeutic potential of these substances from being conducted. The event, which focused on treatment using psychedelics, was organized by the National Academies of Sciences, Engineering and Medicine. Nora Volkow, director of the National Institute on Drug Abuse, has addressed the stressful process that researchers have to go through in order to acquire these controlled substances. During the event, Volkow explained that the scheduling process had made it hard…

MondayApr 11, 2022 9:00 am

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine” Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as a result, psychiatry may never be the same. This isn’t news for companies such as Silo Pharma (OTCQB: SILO). A developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, Silo…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000